NasdaqCM - Delayed Quote USD

Cytosorbents Corporation (CTSO)

Get top stock picks

0.3501 +0.0001 (+0.03%)

At close: September 4 at 4:00:00 PM EDT

0.3500 -0.0001 (-0.03%)

After hours: September 4 at 7:47:56 PM EDT

Get top stock picks

Loading Chart for CTSO

Chart Range Bar

Interval:

In partnership with ChartIQ

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor

CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor

CytoSorbents Announces Reverse Stock Split

CytoSorbents Announces Reverse Stock Split

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ...

CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ...

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

CTSO: CytoSorbents Reports 1st Quarter Financial and Operating Results

CTSO: CytoSorbents Reports 1st Quarter Financial and Operating Results

OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA

OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA

CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights

CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights

Transcript: CytoSorbents Q1 2026 Earnings Conference Call

Transcript: CytoSorbents Q1 2026 Earnings Conference Call

RCEL

VYCO

300642.SZ

AXGN

NMTC

LNSR

RPID

LUCD

APYX

DCTH

Mobilize your Website

View Site in Mobile | Classic

Share by: